CARSGEN-B：ANNOUNCEMENTOFANNUALRESULTSFORTHEYEARENDEDDECEMBER312025ANDPROPOSEDAMENDMENTSTOTHEARTICLESOFASSOCIATIONANDTHEADOPTIONOFTHENINTHAMENDEDANDRESTATEDMEMORANDUMANDARTICLESOFASSOCIATION.pdf

1、1Hong Kong Exchanges and Clearing Limited,The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever f

2、or any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.CARsgen Therapeutics Holdings Limited科 濟 藥 業 控 股 有 限 公 司(Incorporated in the Cayman Islands with limited liability)(Stock Code:2171)ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEM

3、BER 31,2025ANDPROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE NINTHAMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATIONThe board(the“Board”)of directors(the“Directors”)of CARsgen Therapeutics Holdings Limited(the“Company”,“CARsgen Therapeutics”or“CARsgen”)is pleased

4、 to announce the audited consolidated results of the Company,its subsidiaries and consolidated affiliated entities(collectively,the“Group”)for the year ended December 31,2025(the“Reporting Period”),together with the audited comparative figures for the year ended December 31,2024.FINANCIAL HIGHLIGHTS

5、1.REVENUEThe Groups revenue was around RMB125.7 million for the year ended December 31,2025 mainly from zevorcabtagene autoleucel(an autologous BCMA CAR T-cell product),in which the primary revenue of zevorcabtagene autoleucel was calculated on the basis of ex-works price,rather than on the basis of

6、 end-of-market prices.Our revenue is recognized upon completion of ex-works delivery of products.Due to the inherent time cycle of CAR-T manufacturing,there is a discrepancy between the number of orders obtained from Huadong Medicine and number of ex-works deliveries.2.GROSS PROFITThe Groups gross p